Drug name
Last update: Jul 2026Bictegravir (BIC)
Developer(s)
Drug information
Not provided
https://go.drugbank.com/drugs/DB11799
One of the three compounds of Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide)
Small molecule
Integrase strand transfer inhibitor (INSTI)
Bictegravir is an integrase inhibitor used to treat HIV infections. Alternative names are GS-9883 and GS-9883-01. Bictegravir is used in combination with tenofovir alafenamide and emtricitabine to treat human immunodeficiency virus-1 (HIV-1) infection.
In the US, it may be used in treatment-naive patients weighing at least 14 kg. Alternatively, it may be used to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no known or suspected substitutions associated with resistance to bictegravir or tenofovir. In Europe, it is approved for use in patients 2 years of age and older with evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir.
Approved in many HICs and LMICs
Therapeutic area(s)
- HIV
- Treatment
Administration route
Oral
Associated long-acting platforms
Oral solid form
Use of drug
- Self-administered
- Other/Variable/Unknown : once daily within regimen
Dosage
various fixed dose combinations
Not provided
Not provided
Not provided
Associated compounds, formulations and regimens
Bictegravir-PLGA nanoformulation
Ultra-Long-Acting Dimeric Bictegravir Prodrug
Associated technologies
CompareAdditional information
Developer(s)
Gilead
Drug structure
Scale-up and manufacturing prospects
Not provided
Not provided
Not provided
Not provided
Excipients & delivery device(s)
No proprietary excipient used
No novel excipient or existing excipient used
No residual solvent used
No delivery device
Safety, Efficacy and Evidence Summary
Not provided
Not provided
Not provided
Not provided